Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03302936 · ClinicalTrials.gov registry record · Phase 4

Assessing Pyridium for Post-Sling Urinary Retention

A Phase 4 study of Urinary Retention, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 4
Development phase
98
Enrollment target
1
Study location

NCT03302936 is a Phase 4 study of Urinary Retention that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 98 participants, below the 131-participant average among 11 other Urinary Retention trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03302936, a Phase 4 study of Urinary Retention, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 4
Development phase
98 participants
Enrollment target
1
Study location

Study Summary

There has been preliminary data showing that pyridium can decrease the risk of difficulty urinating after midurethral sling. This study is designed to have two groups of patients. One group will receive pyridium pre-operatively, while the other group will have routine preoperative care. Both groups will have their bladder tested prior to going home. It will be evaluated if there is a difference in the difficulty to urinate post-operatively in both groups.

Conditions Studied

Interventions

  • DRUG Phenazopyridine

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2017-10-24
Est. Completion 2019-07-01
Phase Phase 4

What the Registry Record Tells You About NCT03302936

The ClinicalTrials.gov registry entry for NCT03302936 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 11 other Urinary Retention trials with a reported enrollment target (25% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urinary Retention appearing as the primary indexed condition, and to 1 intervention - of which Phenazopyridine is the first listed.

NCT03302936 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03302936 about?

NCT03302936 is a clinical study titled "Assessing Pyridium for Post-Sling Urinary Retention". There has been preliminary data showing that pyridium can decrease the risk of difficulty urinating after midurethral sling. This study is designed to have two groups of patients. One group will receive pyridium pre-operatively, while the other group will have routine preoperative care. Both groups ...

What is the current status of trial NCT03302936?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2017-10-24. Estimated completion is 2019-07-01.

What conditions does trial NCT03302936 study?

This clinical trial studies the following conditions: Urinary Retention.

What interventions are being tested in trial NCT03302936?

The interventions under investigation include: Phenazopyridine (DRUG).

Who is sponsoring clinical trial NCT03302936?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03302936 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Retention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.